Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | TERT | O14746 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | PKM | P14618 | 2/20 | 0.36 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RHEB | Q15382 | 1/20 | 0.34 |
| ▸ | FBP1 | P09467 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21807618 | 0.80 | PKM (0.44) | IDO1LMNATSHRTERTALDH1A1 | |
| SCHEMBL7162341 | 0.76 | TSHR (0.38) | IDO1LMNATSHRALDH1A1HAO1 | |
| SCHEMBL7628635 | 0.74 | IDO1 (0.46) | IDO1LMNATSHRTERTALDH1A1 | |
| SCHEMBL28469527 | 0.71 | CA12 (0.57) | IDO1LMNATSHRTERTALDH1A1 | |
| SCHEMBL1816008 | 0.70 | — | — | |
| SCHEMBL7162549 | 0.70 | MEN1 (0.39) | TSHRALDH1A1KDM4EHSD17B10MEN1 | |
| SCHEMBL8536411 | 0.70 | IDO1 (0.54) | IDO1TERTALDH1A1PKMKDM4E | |
| SCHEMBL6915666 | 0.69 | RHEB (0.55) | LMNATSHRALDH1A1PKMHAO1 | |
| SCHEMBL31464849 | 0.69 | FBP1 (0.55) | IDO1LMNATSHRALDH1A1HAO1 | |
| SCHEMBL225608 | 0.69 | FBP1 (0.55) | IDO1LMNATSHRALDH1A1HAO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0947504-B1 | 16-ENE-VITAMIN D DERIVATIVES | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2003-09-03 | — | — | EP | disclosed |
| US-6555699-B2 | Antitumor and antirheumatic agents, high binding affinity | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-04-29 | — | — | US | disclosed |
| US-20020193616-A1 | 16-ENE-VITAMIN D DERIVATIVES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-12-19 | — | — | US | disclosed |
| US-6433200-B1 | ANTITUMOR AND ANTIRHEUMATIC AGENTS, HIGH BINDING AFINITY TO VITAMIN D RECEPTORS AND WEAK HYPERCALCEMIC ACTIVITY | CHUGEI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-08-13 | — | — | US | disclosed |
| US-20020032340-A1 | 16-ene-vitamin D derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-03-14 | — | — | US | disclosed |
| US-6326503-B1 | ANTITUMOR AGENTS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2001-12-04 | — | — | US | disclosed |
| US-6184398-B1 | ANTITUMOR AGENTS AND TREATMENT OF RHEUMATIC CONDITIONS; HIGH BINDING ABILITY TO VITAMIN D RECEPTORS AND WEAK HYPERCALCEMIC ACTIVITY; E.G.,1,3-DIHYDROXY-20-3-HYDROXY-3-METHYLBUTYLTHIO)-9,10-SECOPREGNA -5,7,10(19),16-TETRAENE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2001-02-06 | — | — | US | disclosed |
| EP-0947504-A1 | 16-ENE-VITAMIN D DERIVATIVES | Chugai Seiyaku Kabushiki Kaisha (JP) | 1999-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193616-A1 | 16-ENE-VITAMIN D DERIVATIVES | VDR, CYP24A1, CYP2R1 | IDO1 3413/4885LMNA 1636/4885TSHR 432/4885 |
| US-20020032340-A1 | 16-ene-vitamin D derivatives | VDR, CYP2R1, CYP24A1 | IDO1 1645/4885LMNA 3455/4885TSHR 333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.